GlaxoSmithKline PLC — Director's Dealing 2017

Feb 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending 17 February 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the ' Company ')

Conditional Share Awards

On 15 February 2017 the Company granted conditional awards to the below Executive Directors and Persons Discharging Managerial Responsibilities. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (DABP) which was approved by shareholders on 20 May 2009.

Participants are required to defer 25% of any bonus earned into Ordinary Shares or ADSs and may be eligible to choose to invest up to an additional 25% (i.e. up to a maximum of 50%) (Deferred Bonus Award).

The Company will match the Deferred Bonus Award up to one-for-one depending on the achievement of performance targets (Matching Award). Details of the performance measures will be confirmed later in the year following shareholder approval of the Remuneration Policy at the AGM on 4 May 2017.

The performance period for the awards is the three financial years from 1 January 2017 to 31 December 2019.

The awards of deferred and matching shares have been granted as conditional awards over ADSs for US pre-tax participants and as nil-cost options over Ordinary Shares for all other participants.

The vesting date for these conditional awards will be the later of the date, following the end of the three year performance period, on which the Remuneration Committee determines the extent to which the performance measures have been achieved, the third anniversary of the Award Date or such other later date as determined by the Remuneration Committee.

The amounts shown below are the maximum amounts payable (exclusive of dividend reinvestment during the performance period). The actual pay-out will be determined by performance over the period. Progress against targets will be reported in the Company's Annual Report yearly.

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Sir Andrew Witty | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Executive Officer | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
As Sir Andrew is retiring from the Company on 31 March 2017 he is
not eligible for a matching award. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 34,353 |
| d) | Aggregated
information | n/a(single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms E Walmsley | |
| --- | --- | --- | --- |
| b) | Position/status | CEO Designate | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 31,945 |
| | | £15.770 | 31,945 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 63,890 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr R G Connor | |
| --- | --- | --- | --- |
| b) | Position/status | President, Global Manufacturing & Supply | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 16,633 |
| | | £15.770 | 16,633 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 33,266 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr L Debruyne | |
| --- | --- | --- | --- |
| b) | Position/status | President, Global Vaccines | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 27,957 |
| | | £15.770 | 27,957 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 55,914 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr S Dingemans | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Financial Officer | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 29,022 |
| | | £15.770 | 29,022 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 58,044 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr N Hirons | |
| --- | --- | --- | --- |
| b) | Position/status | SVP, Global Ethics & Compliance | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 10,513 |
| | | £15.770 | 10,513 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 21,026 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr S A Hussain | |
| --- | --- | --- | --- |
| b) | Position/status | President, Global Pharmaceuticals | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 29,059 |
| | | £15.770 | 29,059 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 58,118 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr B McNamara | |
| --- | --- | --- | --- |
| b) | Position/status | CEO, Consumer Healthcare | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of ADSs (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of ADSs (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject to performance
measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $40.110 | 6,128 |
| | | $40.110 | 6,128 |
| d) | Aggregated
information | n/a (single transaction) | |
| | Aggregated
volume Price | 12,256 $40.110 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D S Redfern | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Strategy Officer | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 13,231 |
| | | £15.770 | 13,231 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 26,462 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr M M Slaoui | |
| --- | --- | --- | --- |
| b) | Position/status | Chairman, Global Vaccines | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of ADSs (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
As Dr Slaoui is retiring from the Company on 30 June 2017 he is not
eligible for a matching award. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $40.110 | 10,760 |
| d) | Aggregated
information | n/a (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms C Thomas | |
| --- | --- | --- | --- |
| b) | Position/status | SVP, Human Resources | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 19,916 |
| | | £15.770 | 19,916 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 39,832 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr P C Thomson | |
| --- | --- | --- | --- |
| b) | Position/status | SVP, Communications & Government Affairs | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 6,269 |
| | | £15.770 | 6,269 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 12,538 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D E Troy | |
| --- | --- | --- | --- |
| b) | Position/status | SVP & General Counsel | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of ADSs (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of ADSs (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject to performance
measures | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $40.110 | 13,005 |
| | | $40.110 | 13,005 |
| d) | Aggregated
information | n/a (single transaction) | |
| | Aggregated
volume Price | 26,010 $40.110 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr P J T Vallance | |
| --- | --- | --- | --- |
| b) | Position/status | President, R&D | |
| c) | Initial
notification/ amendment | Initial Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | 1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan). 2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.770 | 21,632 |
| | | £15.770 | 21,632 |
| d) | Aggregated
information | | |
| | Aggregated
volume Price | 43,264 £15.770 | |
| e) | Date
of the transaction | 2017-02-15 | |
| f) | Place
of the transaction | n/a | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: February
17, 2017
By: VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break